Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28291
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Quach H. | en |
dc.contributor.author | Spencer A. | en |
dc.contributor.author | Kalff A. | en |
dc.date.accessioned | 2021-05-14T09:31:36Z | en |
dc.date.available | 2021-05-14T09:31:36Z | en |
dc.date.copyright | 2012 | en |
dc.date.created | 20121127 | en |
dc.date.issued | 2012-11-27 | en |
dc.identifier.citation | American Journal of Hematology. 87 (12) (pp 1089-1095), 2012. Date of Publication: December 2012. | en |
dc.identifier.issn | 0361-8609 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/28291 | en |
dc.description.abstract | The clinical development of lenalidomide (RevlimidTM), then pomalidomide (ActimidTM) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents. Increased experience and understanding of IMiD's diverse biological effects has lead to rational design of lenalidomide-based treatment-regimens over recent years. However, much about lenalidomide is yet to be understood and fully exploited. Here, we review what is known of lenalidomide's biological effects, clinical certainties and uncertainties in the treatment of MM, and explore its future potential with other synergistic therapeutic agents. © 2012 Wiley Periodicals, Inc. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Wiley-Liss Inc. (111 River Street, Hoboken NJ 07030-5774, United States) | en |
dc.title | Lenalidomide in multiple myeloma: Current status and future potential. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/ajh.23234 | en |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 22641420 [http://www.ncbi.nlm.nih.gov/pubmed/?term=22641420] | en |
dc.identifier.source | 52035313 | en |
dc.identifier.institution | (Quach, Kalff, Spencer) Myeloma Research Group, Australian Centre for Blood Diseases, Monash University, Clayton, VIC, Australia (Quach) Department of Clinical Haematology, Monash Medical Centre, Clayton, VIC, Australia (Quach, Spencer) Department of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia (Kalff, Spencer) Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia | en |
dc.description.address | H. Quach, Myeloma Research Group, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Faculty of Medicine, Nursing and Health Sciences, Level 4, 246 Clayton Rd, Clayton, VIC 3168, Australia. E-mail: hang.quach@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2013 Elsevier B.V., All rights reserved. | en |
dc.identifier.authoremail | Quach H.; hang.quach@monash.edu | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.